Form 4: Bio-Rad Laboratories Executive Kieran O'Kane Reports Stock Transactions
SEC Form 4 Filing
Kieran O'Kane, Chief Commercial Officer of Biodesix Inc., reports the vesting of restricted stock units and subsequent sale of shares to cover taxes.
Summary
- Kieran O'Kane, Chief Commercial Officer of Biodesix Inc. (BDSX), filed a Form 4 detailing changes in beneficial ownership.
- On August 8, 2024, 1,489 restricted stock units (RSUs) vested, each representing a contingent right to receive one share of Biodesix's common stock.
- Following the vesting, shares were sold to cover taxes.
- On August 9, 2024, 345 shares were sold at a price of $1.601 per share.
- On August 12, 2024, 120 shares were sold at a weighted average price of $1.5719 per share, with prices ranging from $1.52 to $1.62.
- After these transactions, O'Kane directly owns 89,628 shares of Biodesix Inc.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment about the company's performance or future prospects.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and their potential impact on stock prices. These filings are closely monitored by investors seeking insights into management's perspective on the company's value and future prospects.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies and their executives.
- The information provided is consistent with SEC regulations and reporting requirements.
- Similar filings are made by executives at comparable companies like Exact Sciences (EXAS) and Guardant Health (GH) when they engage in stock transactions.
Stakeholder Impact
- The stock sales could have a minor impact on the stock price, but the transactions are primarily driven by tax obligations related to RSU vesting.
- The filing provides transparency to shareholders regarding executive stock transactions.
Key Dates
| Date | Description |
|---|---|
| February 8, 2022 | Date from which RSUs vest in sixteen successive quarterly installments. |
| 08/08/2024 | Date of RSU vesting (1,489 units). |
| 08/09/2024 | Date of stock sale (345 shares at $1.601). |
| 08/12/2024 | Date of stock sale (120 shares at $1.5719 weighted average). |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.